Nanoco Group final results release date 13th October 2020

Nanoco Group

Nanoco Group plc (LON:NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other specific nanomaterials emanating from our technology platform, has announced that its final results for the year to 31 July 2020 will be released on 13 October 2020.

Nanoco Group harnesses the power of nano-materials. Nano-materials are materials with dimensions typically in the range 1 – 100 nm. Nano-materials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nano-material that have size-dependent optical and electronic properties. The Group produces quantum dots.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

PPHE Hotel Group refinances Park Plaza Victoria London

PPHE Hotel Group has agreed a new £88 million refinancing facility for Park Plaza Victoria London, replacing an existing loan due to mature in early 2026.

Greggs Plc appoints Richard Smothers as Non-Executive Director

Greggs plc has announced the appointment of Richard Smothers as an independent Non-Executive Director, effective from 1 February 2026.

Hollywood Bowl Group reports FY2025 results with revenue growth

Hollywood Bowl Group has published its audited results for the year ended 30 September 2025, reporting revenue growth of 8.8% to £250.7m and a fourth consecutive year of record revenue and adjusted EBITDA.

Centrica Plc agrees sale of Spirit Energy assets to Serica

Centrica has announced the sale of Spirit Energy’s remaining interests in the Cygnus gas field and other producing assets in the Southern North Sea to Serica Energy.

AstraZeneca’s Enhertu plus pertuzumab approved in US for 1st-line HER2-positive breast cancer

AstraZeneca and Daiichi Sankyo have received US FDA approval for Enhertu in combination with pertuzumab as a 1st-line treatment for adults with unresectable or metastatic HER2-positive breast cancer.

GSK Plc secures UK approval for Exdensur in asthma and nasal polyps

GSK has announced that Exdensur (depemokimab) has received marketing authorisation from the UK MHRA for use in certain asthma and chronic rhinosinusitis with nasal polyps patients.

    Search

    Search